Matrix tablets based on carrageenans with dual controlled release of doxazosin mesylate

International Journal of Pharmaceutics

Volumn 400, Issue 1-2, 2010, Pages 15-23

  Pavli, Matej ^a,b   Vrečer, Franc ^a,b   Baumgartner, Saša ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Krka   (Slovenia)

Author keywords

Carrageenan; Complexation; Controlled release; Doxazosin mesylate; Matrix tablets; Polyelectrolyte

Indexed keywords

CARRAGEENAN; DOXAZOSIN MESYLATE;

ARTICLE; COMPLEX FORMATION; CONTROLLED RELEASE FORMULATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STRUCTURE; HYDRODYNAMICS; IONIC STRENGTH; MATRIX TABLET; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; WATER TRANSPORT; ZETA POTENTIAL;

ADRENERGIC ALPHA-ANTAGONISTS; CALORIMETRY, DIFFERENTIAL SCANNING; CARRAGEENAN; DELAYED-ACTION PREPARATIONS; DOXAZOSIN; EXCIPIENTS; MICROSCOPY, ELECTRON, SCANNING; TABLETS;

EID: 77957667669     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.08.021     Document Type: Article

References (39)

1. Aguzzi C., Bonferoni M.C., Fortich M.R.O., Rossi S., Ferrari F., Caramella C. Influence of complex solubility on formulations based on lambda carrageenan and basic drugs. Pharm. Sci. Technol. 2002, 3:1-7. (article 27).
2. Alderman D.A. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int. J. Pharm. Technol. Prod. Manuf. 1984, 5:1-9.
3. Baumgartner S., Šmid-Korbar J., Vrečer F., Kristl J. Physical and technological parameters influencing floating properties of matrix tablets based on cellulose ethers. S.T.P. Pharma Sci. 1998, 8:285-290.
4. Baumgartner S., Kristl J., Peppas N.A. Network structure of cellulose ethers used in pharmaceutical applications during swelling and at equilibrium. Pharm. Res. 2002, 19:1084-1090.
5. Baumgartner S., Pavli M., Kristl J. Effect of calcium ions on the gelling and drug release characteristics of xanthan matrix tablets. Eur. J. Pharm. Biopharm. 2008, 69:698-707.
6. Bhardwaj T.R., Kanwar M., Lal R., Gupta A. Natural gums and modified natural gums as sustained-release carriers. Drug. Dev. Ind. Pharm. 2000, 26:1025-1038.
7. Bonferoni M.C., Rossi S., Tamayo M., Pedraz J.L., Dominguez, Gil A., Caramella C. On the employment of λ carr in a matrix system. I. Sensitivity to dissolution medium and comparison with Na carboxymethylcellulose and xanthan gum. J. Controlled Release 1993, 26:119-127.
8. Bonferoni M.C., Rossi S., Ferrari F., Bettinetti G.P., Caramella C. Characterization of diltiazem-lambda carrageenan complex. Int. J. Pharm. 2000, 200:207-216.
9. Colombo P., Bettini R., Santi P., Peppas N.A. Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance. PSST 2000, 3:198-204.
10. Coviello T., Matricardi P., Marianecci C., Alhaique F. Polysaccharide hydrogels for modified release formulations. Eur. J. Pharm. Biopharm. 2007, 66:200-209.
11. De Ruiter G.A., Rudolph B. Carrageenan biotechnology. Trends Food Sci. Technol. 1997, 8:389-395.
12. Delgado A.V., Gonzalez-Caballero F., Hunter R.J., Koopal L.K., Lyklema J. Measurement and interpretation of electrokinetic phenomena. Pure Appl. Chem. 2005, 77:1753-1805.
13. Esbelin B., Beyssac E., Aiache J.M., Shiu G.K., Skelly J.P. A new method of dissolution in vitro, the bio-dis apparatus: comparison with the rotating bottle method and in vitro: in vivo correlations. J. Pharm. Sci. 2006, 80:991-994.
14. Grčman M., Vrečer F., Meden A. Some physico-chemical properties of doxazosin mesylate polymorphic forms and its amorphous state. J. Therm. Anal. Calorim. 2002, 68:575-587.
15. Gupta V.K., Hariharan M., Wheatley T.A., Price J.C. Controlled-release tablets from carrageenans: effect of formulation, storage and dissolution factors. Eur. J. Pharm. Biopharm. 2001, 51:241-248.
16. Hariharan M., Wheatley T.A., Price J.C. Controlled-release tablet matrices from carrageenans: compression and dissolution studies. Pharm. Dev. Technol. 1997, 2:383-393.
17. Herbig S.M., Cardinal J.R., Korsmeyer R.W., Smith K.L. Asymmetric-membrane tablet coatings for osmotic drug delivery. J. Controlled Release 1995, 35:127-136.
18. Hugerth A.M. Micropolarity and microviscosity of amitriptyline and dextran sulfate/carrageenan-amitriptyline systems: the nature of polyelectrolyte-drug complexes. J. Pharm. Sci. 2001, 90:1665-1677.
19. Janaswamy S., Chandrasekaran R. Three-dimensional structure of the sodium salt of iota-carrageenan. Carbohydr. Res. 2001, 335:181-194.
20. Kalantzi L., Persson E., Polentarutti B., Abrahamsson B., Goumas K., Dressman J.B., Reppas C. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm. Res. 2006, 23:1373-1381.
21. 1 adrenoceptor ligands. Bioorg. Med. Chem. 2006, 14:1580-1587.
22. Lelham N.C., Sundelöf L.O. Some aspects on characterization and properties of charged polysaccharides. An investigation of the system carrageenan/amitriptyline/water with relation to amphiphile adsorption and charge density. Int. J. Pharm. 1995, 115:103-111.
23. + effects on the gelation properties of n-carrageenan. Biophys. Chem. 2005, 113:129-135.
24. Naim S., Samuel B., Chauhan B., Paradkar A. Effect of potassium chloride and cationic drug on swelling, erosion and release from κ-carrageenan matrices. Pharm. Sci. Technol. 2004, 5:1-8. (Article 25).
25. Nerurkar J., Jun H.W., Price J.C., Park M.O. Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: effect of formulation factors on dissolution rates. Eur. J. Pharm. Biopharm. 2005, 61:56-68.
26. Nilsson S., Piculell L. Helix-coil transitions of ionic polysaccharides analyzed within the Poisson-Boltzmann cell model. 4. Effects of site-specific counterion binding. Macromolecules 1991, 24:3804-3811.
27. Omidian H., Park K.J. Swelling agents and devices in oral drug delivery. Drug Deliv. Sci. Technol. 2008, 18:83-93.
28. Pavli M., Vrečer F., Baumgartner S. Interactions of biopolymers carrageenans with cationic drug doxazosin mesylate characterized by means of differential scanning calorimetry. Pharmazie 2010, 65:525-526.
29. Picker K.M. The use of carrageenan in mixture with microcrystalline cellulose and its functionality for making tablets. Eur. J. Pharm. Biopharm. 1999, 48:27-36.
30. Picker K.M. Matrix tablets of carrageenans. II. Release behavior and effect of added cations. Drug Dev. Ind. Pharm. 1999, 25:339-346.
31. Rees D.A. Polysaccharide Shapes 1977, Chapman and Hall, London.
32. +. J. Phys. Chem. B 1998, 102:11024-11028.
33. Rochas C., Lahaye M., Yaphe W. Sulfate content of carrageenan and agar determined by infrared spectroscopy. Bot. Mar. 1986, 29:335-340.
34. Rowe R.C., Sheskey P.J., Weller P.J. Carrageenan. Handbook of Pharmaceutical Excipients 2005, Pharmaceutical Press, London, pp. 101-103. 5th ed.
35. Singh S.K., Lelham N.C. Thermodynamics of κ-carrageenan-amphiphilic drug interaction as influenced by specific counterions and temperature: a microcalorimetric and viscometric study. J. Colloid Interface Sci. 1998, 203:430-446.
36. 13C high resolution NMR spectroscopy of carrageenans: application in research and industry. Trends Food Sci. Technol. 2002, 13:73-92.
37. 1 antagonists. Foye's Principles of Medicinal Chemistry 2002, Lippincott Williams & Wilkins, Philadelphia, pp. 306-307. 5th ed.
38. Yuguchi Y., Thuy T.T.T., Urakawa H., Kajiwara K. Structural characteristics of carrageenan gels: temperature and concentration dependence. Food Hydrocoll. 2002, 16:515-522.
39. Yuguchi Y., Urakawa H., Kajiwara K. Structural characteristics of carrageenan gels: various types of counter ions. Food Hydrocoll. 2003, 17:481-485.